New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:55 EDTACAD, ACAD, ATTU, ATTU, CODE, CODE, AERI, AERI, EGAN, EGAN, IMAX, IMAX, SPNS, SPNS, JAKK, JAKK, CNAT, CNAT, BIRT, BIRT, BDSI, BDSI, PERI, PERIRoth Capital to hold a conference
26th Annual Growth Stock Conference is being held in Dana Point, California on March 9-12 with webcasted company presentations to begin on March 10 at 11 am; not all company presentations may be webcasted. Webcast Link
News For ACAD;BDSI;BIRT;CNAT;JAKK;SPNS;IMAX;EGAN;AERI;CODE;ATTU;PERI From The Last 14 Days
Check below for free stories on ACAD;BDSI;BIRT;CNAT;JAKK;SPNS;IMAX;EGAN;AERI;CODE;ATTU;PERI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2014
05:38 EDTJAKKJAKKS Pacific removed from Focus List at B. Riley
Subscribe for More Information
July 25, 2014
10:02 EDTIMAXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:41 EDTIMAXIMAX upgraded to Buy from Hold at Benchmark Co.
Subscribe for More Information
07:33 EDTIMAXIMAX shares attractive at current levels, says JPMorgan
Subscribe for More Information
July 24, 2014
12:39 EDTEGANeGain management to meet with Benchmark Co.
Meetings to be held in Boston on July 30 and in Philadelphia on July 31 hosted by Benchmark Co.
07:33 EDTAERIAerie receives NOL for Rhopressa Phase 3 registration trial
Aerie Pharmaceuticals announced that it has received a No Objection Letter from Health Canada to conduct a Phase 3 registration trial of Rhopressa. The study, named “Rocket 3,” is designed to evaluate safety and tolerability of Rhopressa in patients over 12 months and is part of a broad Phase 3 program being conducted by Aerie. The company recently announced the commencement of two Phase 3 trials in the U.S., “Rocket 1” and “Rocket 2,” which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa. The company said, " Pending progress of the program and regulatory approvals, Aerie intends to commercialize Rhopressa in North American markets with its own sales force and will seek commercialization partners in other key territories, including Europe and Japan. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030."
07:21 EDTATTUAttunity Ltd reports Q2 adjusted EPS (3c), consensus 5c
Reports Q2 revenue $8.29M, consensus $8.36M.
07:06 EDTIMAXIMAX reports theater network as of June 30 was 868 systems
Subscribe for More Information
07:05 EDTIMAXIMAX reports Q2 adjusted EPS 25c, consensus 21c
Subscribe for More Information
July 23, 2014
10:02 EDTCODEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:06 EDTJAKKJAKKS Pacific raises FY14 EPS to 40c-45c from 30c-40c, consensus 40c
Raises FY14 revenue to $660M-$670M from $633M-$640M, consensus $649.84M; Raises FY14 EBITDA to $42M-$44M from $41M-$43M
06:04 EDTJAKKJAKKS Pacific reports Q2 EPS (43c), consensus (29c)
Subscribe for More Information
July 22, 2014
18:06 EDTCODESpansion upgraded to Buy from Hold at Jefferies
Jefferies upgraded Spansion to Buy citing the potential for margin upside and the company's ability to monetize its intellectual property. The firm raised its price target for shares to $28 from $21.
07:04 EDTCODESpansion has positive read through from Texas Instruments, says Sterne Agee
Sterne Agee believes that Texas Instruments' (TXN) commentary on 4G telecom, auto and industrial strength should be positive for Spansion (CODE). The firm keeps a Buy rating on Spansion.
July 21, 2014
18:07 EDTIMAXIMAX adds 19 theaters throughout China with Shanghai Film Corp
IMAX announced an agreement with Shanghai Film Corporation and its subsidiaries for 19 IMAX theaters to be located in new construction projects throughout China. Nearly all of the 19 sites, which will be sales agreements, have been identified, with a significant number scheduled for installation before the end of 2015.
17:18 EDTCODESpansion challenges Macronix patent claims
Spansion has filed petitions with the USPTO's Patent Trial and Appeal Board to invalidate the patents that are being asserted against Spansion by Macronix International and Macronix America in an investigation that is currently pending at the U.S. International Trade Commission. In its petitions, Spansion challenges the validity of three patents addressing technologies directed to circuit designs and circuit layouts. The PTAB's decision on granting these petitions is expected in early 2015.
10:19 EDTJAKKHasbro tumbles after lower games performance weighs on sales
Subscribe for More Information
10:02 EDTIMAXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:43 EDTIMAXIMAX upgraded to Buy from Hold at Stifel
Subscribe for More Information
July 17, 2014
10:55 EDTJAKKMattel topples after Q2 earnings miss estimates
Shares of global toy product manufacturer Mattel (MAT), are toppling over after the company's second quarter earnings results fell below analysts' consensus. WHAT'S NEW: Mattel's reported Q2 earnings per share of 8c, which was not comparable to a consensus of 18c since the company said its EPS number included a tax benefit of 11c per share and a negative impact of 7c per share of MEGA Brands acquisition and integration costs. Excluding both of these items, EPS was 3c per share. Mattel's Q2 revenue was $1.06B, which missed analysts' consensus estimates of $1.19B. For Q2, the company reported that its Girls and Boys Brands sales were down 13%, Fisher-Price Brands sales were down 17%, American Girl Bands revenue was up 6% and revenue from its Construction and Arts & Crafts Brands was $61.6M. WHAT'S NOTABLE: During its earnings conference conference call, Mattel said that it plans to increase advertising spending in the second half of the year to build momentum for key brands. It sees improving global trends in point-of-sale but says the company still has a lot of work to do to improve those trends. As Mattel looks to the third quarter, it sees continued challenges from current headwinds. With the MEGA brands deal now closed, the company aims to improve profitability of MEGA brands on a global basis and believes the acquisition will be accretive to earnings in fiscal year 2015. It expects lower international sales and is investing heavily in markets in Russia and China. Mattel is looking to maintain gross margins in the low to mid-50% range in near term. It noted that it aims to achieve a modest increase in SG&A due to severance and ongoing growth investments, excluding the MEGA Brands acquisition. Inventory fair value adjustment related to existing MEGA Brands-owned inventory should wind down in Q3, the company said. Amortization is expected to decrease to $17M in 2015 and $9M in 2016. PRICE ACTION: Shares of Mattel are down $2.31, or 5.92%, to $36.72 in morning trading. OTHERS TO WATCH: Mattel peer Hasbro (HAS), which reports quarterly earnings on July 21, is relatively flat at $52.59. JAKKS Pacific (JAKK) is up almost 1.5% to $8.20 and and LeapFrog (LF) is up 3.02% to $7.66.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use